A Prospective Study of Instrumented, Posterolateral Lumbar Fusions (PLF) With OsteoAMP®
Status: | Active, not recruiting |
---|---|
Conditions: | Orthopedic |
Therapuetic Areas: | Orthopedics / Podiatry |
Healthy: | No |
Age Range: | 21 - 85 |
Updated: | 4/15/2017 |
Start Date: | September 2015 |
End Date: | May 2019 |
A Prospective Study of Instrumented, Posterolateral Lumbar Fusions (PLF) With OsteoAMP® to Evaluate Long-Term Safety and Efficacy in Patients Requiring 1-2 Level Instrumented PLF
OsteoAMP is an allograft (transplantation of part of one person to another person) derived
growth factor rich bone graft for use in spinal fusion. The study is designed to obtain a
higher level of clinical evidence for OsteoAMP in spinal fusion procedures and not to garner
FDA regulatory approval. This is a prospective, non-randomized, non-controlled, multi-center
study of OsteoAMP in instrumented, posterolateral lumbar fusion (PLF) in patients with
degenerative disc disease, degenerative spondylolisthesis (up to grade 1), and/or mild
degenerative scoliosis, up to 25 degree curvature. Patients that are scheduled to undergo
instrumented, posterolateral spinal fusion surgery as part of their medical treatment and
comply with the study eligibility criteria will be given the opportunity to consent and be
entered into the study.
growth factor rich bone graft for use in spinal fusion. The study is designed to obtain a
higher level of clinical evidence for OsteoAMP in spinal fusion procedures and not to garner
FDA regulatory approval. This is a prospective, non-randomized, non-controlled, multi-center
study of OsteoAMP in instrumented, posterolateral lumbar fusion (PLF) in patients with
degenerative disc disease, degenerative spondylolisthesis (up to grade 1), and/or mild
degenerative scoliosis, up to 25 degree curvature. Patients that are scheduled to undergo
instrumented, posterolateral spinal fusion surgery as part of their medical treatment and
comply with the study eligibility criteria will be given the opportunity to consent and be
entered into the study.
The objective of this clinical study are: to evaluate the long term efficacy of OsteoAMP in
patients requiring 1 to 2 adjacent level, instrumented posterolateral spinal fusion
procedure of the lumbar or lumbosacral spine, and to evaluate OsteoAMP in spinal fusion
procedures based on fusion results, adverse event rates, and pain and health scores.
Patients that are scheduled to undergo instrumented, posterolateral spinal fusion (PLF)
surgery as part of their medical treatment and comply with the study eligibility criteria
will be recruited and entered into the study. Subjects recruited into the study will receive
OsteoAMP as part of an instrumented PLF surgical procedure. The surgery may also include
nerve root decompressions through laminectomies and foraminotomies. As is consistent with
the current standard of care.
The study involves consecutive patients suffering from lower back and leg pain due to
degenerative disc disease (DDD), degenerative spondylolisthesis (up to grade 1), and/or mild
degenerative scoliosis that are candidates for an instrumented PLF with pedicle screws in 1
or 2 motion segments of the lumbar or lumbosacral spine. Patients will require a total bone
graft volume of at least 10cc per side per level in the PLF procedure, including OsteoAMP
granules hydrated with bone marrow aspirate (BMA) and local autogenous bone.
Subjects will be followed for 24 months post-surgery.
patients requiring 1 to 2 adjacent level, instrumented posterolateral spinal fusion
procedure of the lumbar or lumbosacral spine, and to evaluate OsteoAMP in spinal fusion
procedures based on fusion results, adverse event rates, and pain and health scores.
Patients that are scheduled to undergo instrumented, posterolateral spinal fusion (PLF)
surgery as part of their medical treatment and comply with the study eligibility criteria
will be recruited and entered into the study. Subjects recruited into the study will receive
OsteoAMP as part of an instrumented PLF surgical procedure. The surgery may also include
nerve root decompressions through laminectomies and foraminotomies. As is consistent with
the current standard of care.
The study involves consecutive patients suffering from lower back and leg pain due to
degenerative disc disease (DDD), degenerative spondylolisthesis (up to grade 1), and/or mild
degenerative scoliosis that are candidates for an instrumented PLF with pedicle screws in 1
or 2 motion segments of the lumbar or lumbosacral spine. Patients will require a total bone
graft volume of at least 10cc per side per level in the PLF procedure, including OsteoAMP
granules hydrated with bone marrow aspirate (BMA) and local autogenous bone.
Subjects will be followed for 24 months post-surgery.
Summary of Inclusion Criteria:
1. Aged 21 to 85 years and skeletally mature at time of surgery
2. Diagnosis of degenerative disc disease (DDD), degenerative spondylolisthesis (up to
grade 1), and/or mild degenerative scoliosis (up to 25°) curvature
3. One or more of the following are met: -instability (defined a angulation greater than
or equal to 5 degrees and/or translation greater than or equal 4mm based on
flexion/extension radiographs, -osteophyte formation, - decreased disc height, -
thickening of ligamentous tissue, disc degeneration or herniation,- facet joint
degeneration
4. Requires fusion (i.e., Symptomatic) at up to two contiguous levels from L1 to S1.
5. Preoperative ODI score of more than 30
6. Non-responsive to non-operative treatment for at least 6 months.
7. Lower back pain with or without claudication.
8. If of child-bearing potential, non-pregnant, non-nursing, and agrees to use
contraception for up to 2 years following surgery
9. Willing and able to comply with study plan and able to understand and sign informed
consent
Summary of Exclusion Criteria
1. Primary diagnosis of a spinal disorder other than DDD, degenerative spondylolisthesis
up to Grade 1 or mild degenerative scoliosis of up to 25 degrees curvature
2. Requires fusion of more than 2 vertebral levels or of 2 non-adjacent vertebral levels
3. Conditions requiring medications that interfere with fusion or bone metabolism
4. More than one immobile vertebral level between L1 and S1 from any cause
5. Overt or active local or systemic infection, including latent infection around the
surgical implantation site
6. Clinically severe obesity as defined by the National Institutes of Health
7. Uncontrolled diabetes mellitus as confirmed by HbA1c greater than 8%
8. History of osteoporosis or other metabolic bone disorders, including Paget's disease
and osteomalacia
9. History of hypersensitivity to any of the agents used to process OsteoAMP
10. History of autoimmune disease
11. Received other bone graft substitutes
12. Received medication that may interfere with fusion or bone metabolism within 2 weeks
of planned surgery
13. Received or plans to receive investigational therapy
14. Presence of active malignancy unless he/she has been treated with curative intent and
there have been no clinical signs or symptoms of malignancy for at least 3 years
15. Presence of systemic disease or condition, which affects his/her ability to
participate in the study requirements or the ability to evaluate the efficacy of the
product
16. Prisoner, transient, or has been treated for chemical/alcohol dependency in an
inpatient substance abuse program within 6 months prior to study enrollment or has
significant psychosocial disturbance that would affect participation in the study, in
the opinion of the investigator
17. Any condition for which the surgical procedure, in the opinion of the Investigator,
poses an undue risk
18. Pursuing litigation related to cervical and/or lumbar/lumbosacral spine
We found this trial at
11
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Charlotte, NC, North Carolina 28207
Principal Investigator: R. Alden Milam, MD
Phone: 704-323-3697
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
Chicago, Illinois 60612
(312) 942-5000
Principal Investigator: Howard An, MD
Phone: 312-942-6689
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
Click here to add this to my saved trials
Egg Harbor Township, New Jersey 08234
Principal Investigator: Barrett Woods, MD
Phone: 609-515-3464
Click here to add this to my saved trials
Kansas City, Kansas 66160
Principal Investigator: Douglas Burton, MD
Phone: 913-588-0581
Click here to add this to my saved trials
Laguna Hills, California 92653
Principal Investigator: Robert Jackson, MD
Phone: 949-588-5800
Click here to add this to my saved trials
Morgantown, West Virginia 26506
(304) 293-0111
Principal Investigator: Scott Daffner, MD
Phone: 304-293-1074
West Virginia University West Virginia University, founded in 1867, has a long and rich history...
Click here to add this to my saved trials
New Haven, Connecticut 6520
(203) 432-4771
Principal Investigator: Peter Whang, MD
Phone: 203-785-2542
Yale University Yale's roots can be traced back to the 1640s, when colonial clergymen led...
Click here to add this to my saved trials
Paducah, Kentucky 42001
Principal Investigator: Clint Hill, MD
Phone: 270-442-9461
Click here to add this to my saved trials
Click here to add this to my saved trials